Monitoring Report: Respiratory Viruses - January 2025 Data

Samuel Gratzl*, PhD

Brianna M Goodwin Cartwright*, MS

Karen Gilbert, PhD

Patricia J Rodriguez, PhD, MPH

Duy Do, PhD

Nicholas L Stucky, MD, PhD

*Denotes co-first author
Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Dr Nicholas Stucky
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: nicholass@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through February 02, 2025) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2020 and February 02, 2025. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 697,733 hospitalizations of 643,063 unique patients who tested positive for a respiratory virus between October 01, 2020 and February 02, 2025.

Overall, the rate of hospitalizations associated with respiratory viruses slightly increased from late December 2024 into January 2025. Between the last week of December and the week ending January 27, there was a 3.1% increase in respiratory virus-associated hospitalizations; respiratory virus-associated hospitalizations accounted for 9.6% of all hospitalizations. There was a large increase in influenza-associated hospitalizations (+53.8%), which rose from 4.4% to 6.8% of all hospitalizations. In contrast, hospitalization rates associated with other respiratory viruses declined. The population 0-4 years old and over 65 saw similar increases in influenza-associated hospitalizations; the hospitalization rate at the end of January is 2-fold greater than last season's peak (October 2023 – September 2024). The population over 65 also saw increases in rhinovirus-associated hospitalizations.

Discussion: These data highlight a shifting landscape in respiratory virus-associated hospitalizations, with influenza emerging as the primary concern. While overall hospitalizations associated with respiratory viruses saw only a slight increase, influenza-associated hospitalizations rose dramatically across all age groups, particularly in young children and older adults. Conversely, RSV and COVID-associated hospitalizations declined, marking a shift from previous trends. These findings

underscore the importance of continued surveillance and public health measures to address the evolving impact of respiratory viruses, ensuring that rising influenza activity does not place additional strain on healthcare systems.

Trends in surveillance

Overall population

	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 30, 2024	9.3%	2.5%	4.4%	0.2%	0.1%	1.8%	0.9%
January 27, 2025	9.6%	1.8%	6.8%	0.1%	0.1%	0.9%	0.6%
Change (percentage)	+3.1%	-28.2%	+53.8%	-26.2%	-47.7%	-50.5%	-35.0%
Difference (percentage points)	+0.3%	-0.7%	+2.4%	-0.0%	-0.1%	-0.9%	-0.3%

	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 30, 2024	10.9%	6.9%	16.2%	1.6%	1.9%	10.4%	10.7%
January 27, 2025	13.5%	5.6%	24.6%	1.2%	0.9%	5.3%	8.4%
Change (percentage)	+24.3%	-19.8%	+52.6%	-24.5%	-53.3%	-48.6%	-21.6%
Difference (percentage points)	+2.6%	-1.4%	+8.5%	-0.4%	-1.0%	-5.0%	-2.3%

In the week of January 27, 2025, respiratory virus-associated hospitalizations accounted for 9.6% of all hospitalizations, a slight increase from 9.3% in late December (+3.1%). The largest increase in hospitalization rates was observed for influenza (+53.8%), rising from 4.4% to 6.8% of all hospitalizations. In contrast, notable declines were seen for all other respiratory viruses; COVID (-28.2%), RSV (-50.5%), rhinovirus (- 35.0%), HMPV (-26.2%), and parainfluenza (-47.7%). Influenza test positivity saw the largest increase (+52.6%) between the last full week of December 2024 and January 2025, rising by 8.5 percentage points to 24.6%. Test positivity for all other respiratory viruses declined. This marks the highest recorded rate of influenza-associated hospitalizations in these data. The rate of influenza-associated hospitalizations associated is 1.8-fold greater than last season.

Infants and children (age 0-4)

	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 30, 2024	7.3%	1.6%	0.8%	0.2%	0.2%	5.1%	1.2%
January 27, 2025	5.3%	1.0%	1.4%	0.2%	0.1%	1.5%	1.9%
Change (percentage)	-27.6%	-33.2%	+91.2%	-18.5%	-53.4%	-69.8%	+53.7%
Difference (percentage points)	-2.0%	-0.5%	+0.7%	-0.0%	-0.1%	-3.6%	+0.7%

	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 30, 2024	17.4%	6.4%	17.8%	2.9%	5.2%	32.6%	22.4%
January 27, 2025	17.2%	5.5%	27.6%	2.7%	2.3%	16.4%	25.9%
Change (percentage)	-1.1%	-13.8%	+54.6%	-6.6%	-55.3%	-49.7%	+15.9%
Difference (percentage points)	-0.2%	-0.9%	+9.7%	-0.2%	-2.9%	-16.2%	+3.6%

In the population aged 0–4 years, respiratory virus-associated hospitalizations declined by 27.6% from late December to the week of January 27, now accounting for 5.3% of all hospitalizations in this age group. However, trends varied across specific viruses. Influenza-associated hospitalizations saw the largest increase (+91.2%), rising by 0.7 percentage points to 1.4%. The current rate of influenza-associated hospitalizations is 2-fold higher than the peak of last season for this age group. Conversely, RSV-associated hospitalizations experienced the sharpest decline (-69.8%), dropping by 3.6 percentage points to 1.5%. Notable decreases were also recorded for COVID (-33.2%), HMPV (-18.5%), and parainfluenza (-53.4%). Rhinovirus hospitalizations, however, increased by 53.7% (+0.7 percentage points). Influenza test positivity also saw the largest increase (+54.6%), rising by 9.7 percentage points to 27.6% between the end of December 2024 and the end of January 2025. Rhinovirus test positivity also rose (+15.9%). In contrast, RSV test positivity dropped sharply (-49.7%), while declines were also observed for COVID (-13.8%), HMPV (-6.6%), and parainfluenza (-55.3%). These shifts indicate a changing respiratory virus landscape in young children, with influenza- and rhinovirus-associated hospitalizations increasing, while RSV- and other respiratory viruses-associated hospitalizations decline.

Older adults (age 65 and over)

	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 30, 2024	11.8%	3.7%	5.4%	0.2%	0.1%	2.0%	0.9%
January 27, 2025	11.9%	2.4%	8.4%	0.1%	0.1%	1.1%	0.4%
Change (percentage)	+0.4%	-34.1%	+57.1%	-28.9%	-54.5%	-46.1%	-51.8%

	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
Difference (percentage points)	+0.0%	-1.3%	+3.1%	-0.1%	-0.1%	-0.9%	-0.5%

	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
December 30, 2024	8.4%	9.1%	11.6%	1.5%	1.2%	5.8%	7.1%
January 27, 2025	9.6%	6.9%	18.3%	1.0%	0.5%	3.6%	3.3%
Change (percentage)	+14.2%	-24.7%	+57.9%	-33.5%	-61.5%	-37.4%	-53.4%
Difference (percentage points)	+1.2%	-2.3%	+6.7%	-0.5%	-0.8%	-2.2%	-3.8%

Among older adults (age 65 and over), there was a minimal increase in respiratory virus-associated hospitalizations from late December to the end of January 2025 (+0.4%). Respiratory virus-associated hospitalizations now account for 11.9% of hospitalizations in this age group. However, large shifts were observed among specific viruses. Influenza-associated hospitalizations saw the largest increase (+57.1%), rising by 3.1 percentage points to 8.4% of all hospitalizations in this age group. The current rate of influenza-associated hospitalizations is 2-fold higher than the peak of last season for this age group. Conversely, notable declines were recorded for RSV-(- 46.1%), COVID- (-34.1%), rhinovirus- (-51.8%), HMPV- (-28.9%), and parainfluenza-associated (- 54.5%) hospitalizations. RSV- and COVID-associated hospitalizations now account for 1.1% and 2.4% of all hospitalizations in this population. Influenza test positivity saw the largest increase (+57.9%), rising by 6.7 percentage points to 18.3% between December 2024 and January 2025. Test positivity for all other respiratory viruses decreased during this period. These trends highlight the evolving landscape of respiratory virus impact in older adults, with influenza emerging as an increasing concern as other respiratory viruses decline.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding

of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2020 and February 02, 2025 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on February 13, 2025 and included de-identified patient care data primarily located across ten states: New York, Florida, Virginia, California, Illinois, Ohio, Washington, North Carolina, Wisconsin, and Louisiana.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first

day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 697,733 hospitalizations of 643,063 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	176,588 (100.00%)	183,127 (100.00%)	127,840 (100.00%)	113,794 (100.00%)	41,714 (100.00%)	643,063 (100.00%)
Age Group						
< 6 months	1,301 (0.74%)	2,494 (1.36%)	3,149 (2.46%)	2,463 (2.16%)	796 (1.91%)	10,203 (1.59%)
6 - <12 months	510 (0.29%)	1,126 (0.61%)	1,493 (1.17%)	1,253 (1.10%)	507 (1.22%)	4,889 (0.76%)
1 - <2 years	911 (0.52%)	1,708 (0.93%)	2,055 (1.61%)	1,724 (1.52%)	788 (1.89%)	7,186 (1.12%)
2 - 4 years	1,059 (0.60%)	2,514 (1.37%)	3,192 (2.50%)	2,234 (1.96%)	1,005 (2.41%)	10,004 (1.56%)
5 - 17 years	1,862 (1.05%)	3,167 (1.73%)	3,594 (2.81%)	3,113 (2.74%)	1,288 (3.09%)	13,024 (2.03%)
18 - 49 years	40,252 (22.79%)	38,786 (21.18%)	17,866 (13.98%)	15,233 (13.39%)	5,918 (14.19%)	118,055 (18.36%)
50 - 64 years	44,567 (25.24%)	37,599 (20.53%)	20,277 (15.86%)	18,485 (16.24%)	7,361 (17.65%)	128,289 (19.95%)
65 - 74 years	36,744 (20.81%)	36,758 (20.07%)	25,170 (19.69%)	22,870 (20.10%)	8,363 (20.05%)	129,905 (20.20%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
75 - 84 years	31,360 (17.76%)	35,830 (19.57%)	29,588 (23.14%)	27,365 (24.05%)	9,404 (22.54%)	133,547 (20.77%)
85+ years	18,022 (10.21%)	23,145 (12.64%)	21,456 (16.78%)	19,054 (16.74%)	6,284 (15.06%)	87,961 (13.68%)
Sex						
Female	85,883 (48.63%)	93,910 (51.28%)	66,900 (52.33%)	59,286 (52.10%)	22,033 (52.82%)	328,012 (51.01%)
Male	88,956 (50.37%)	87,418 (47.74%)	59,818 (46.79%)	53,275 (46.82%)	19,283 (46.23%)	308,750 (48.01%)
Other	2 (0.00%)	2 (0.00%)	4 (0.00%)	0	0	8 (0.00%)
Unknown	1,747 (0.99%)	1,797 (0.98%)	1,118 (0.87%)	1,233 (1.08%)	398 (0.95%)	6,293 (0.98%)
Race						
White	112,464 (63.69%)	123,261 (67.31%)	85,734 (67.06%)	74,693 (65.64%)	27,095 (64.95%)	423,247 (65.82%)
Black or African American	21,891 (12.40%)	21,709 (11.85%)	14,178 (11.09%)	13,861 (12.18%)	6,010 (14.41%)	77,649 (12.07%)
Asian	4,427 (2.51%)	4,411 (2.41%)	4,190 (3.28%)	3,340 (2.94%)	1,194 (2.86%)	17,562 (2.73%)
Native Hawaiian or Other Pacific Islander	914 (0.52%)	956 (0.52%)	661 (0.52%)	640 (0.56%)	245 (0.59%)	3,416 (0.53%)
American Indian or Alaska Native	1,029 (0.58%)	1,124 (0.61%)	820 (0.64%)	660 (0.58%)	260 (0.62%)	3,893 (0.61%)
Other Race	12,417 (7.03%)	10,348 (5.65%)	8,404 (6.57%)	7,273 (6.39%)	2,913 (6.98%)	41,355 (6.43%)
Unknown	23,446 (13.28%)	21,318 (11.64%)	13,853 (10.84%)	13,327 (11.71%)	3,997 (9.58%)	75,941 (11.81%)
Ethnicity						
Hispanic or Latino	20,305 (11.50%)	16,927 (9.24%)	13,239 (10.36%)	12,850 (11.29%)	5,220 (12.51%)	68,541 (10.66%)
Not Hispanic or Latino	130,451 (73.87%)	144,170 (78.73%)	100,751 (78.81%)	90,394 (79.44%)	33,825 (81.09%)	499,591 (77.69%)
Unknown	25,832 (14.63%)	22,030 (12.03%)	13,850 (10.83%)	10,550 (9.27%)	2,669 (6.40%)	74,931 (11.65%)
Virus						
COVID	165,382 (93.65%)	159,083 (86.87%)	77,552 (60.66%)	61,827 (54.33%)	12,363 (29.64%)	476,207 (74.05%)
HMPV	90 (0.05%)	2,323 (1.27%)	4,069 (3.18%)	3,258 (2.86%)	598 (1.43%)	10,338 (1.61%)
RSV	2,054 (1.16%)	4,463 (2.44%)	8,106 (6.34%)	9,889 (8.69%)	5,485 (13.15%)	29,997 (4.66%)
influenza	405 (0.23%)	4,937 (2.70%)	17,764 (13.90%)	20,507 (18.02%)	16,221 (38.89%)	59,834 (9.30%)
parainfluenza	1,503 (0.85%)	2,435 (1.33%)	4,414 (3.45%)	3,658 (3.21%)	970 (2.33%)	12,980 (2.02%)
rhinovirus	7,154 (4.05%)	9,886 (5.40%)	15,935 (12.46%)	14,655 (12.88%)	6,077 (14.57%)	53,707 (8.35%)
Comorbidity						

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Asthma	14,938 (8.46%)	18,334 (10.01%)	15,695 (12.28%)	15,234 (13.39%)	6,404 (15.35%)	70,605 (10.98%)
Chronic Lung Disease	11,402 (6.46%)	12,414 (6.78%)	9,909 (7.75%)	9,607 (8.44%)	3,933 (9.43%)	47,265 (7.35%)
Chronic Obstructive Pulmonary Disease	19,936 (11.29%)	27,296 (14.91%)	22,846 (17.87%)	22,054 (19.38%)	8,666 (20.77%)	100,798 (15.67%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020

Test positivity rate over time

We included 51,489,139 lab results with known results of which 4,868,711 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2020

Weekly test positivity rate since October 2020

blue background indicate respiratory virus season (Oct - Sep)

COVID-19

Our COVID study population consists of 493,331 hospitalizations of 476,207 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	165,382 (100.00%)	159,083 (100.00%)	77,552 (100.00%)	61,827 (100.00%)	12,363 (100.00%)	476,207 (100.00%)
Age Group						
< 6 months	317 (0.19%)	773 (0.49%)	430 (0.55%)	373 (0.60%)	154 (1.25%)	2,047 (0.43%)
6 - <12 months	57 (0.03%)	271 (0.17%)	214 (0.28%)	229 (0.37%)	99 (0.80%)	870 (0.18%)
1 - <2 years	105 (0.06%)	278 (0.17%)	193 (0.25%)	266 (0.43%)	197 (1.59%)	1,039 (0.22%)
2 - 4 years	132 (0.08%)	426 (0.27%)	261 (0.34%)	312 (0.50%)	275 (2.22%)	1,406 (0.30%)
5 - 17 years	940 (0.57%)	1,412 (0.89%)	578 (0.75%)	626 (1.01%)	414 (3.35%)	3,970 (0.83%)
18 - 49 years	38,242 (23.12%)	35,253 (22.16%)	10,191 (13.14%)	6,710 (10.85%)	1,150 (9.30%)	91,546 (19.22%)
50 - 64 years	42,811 (25.89%)	34,027 (21.39%)	11,848 (15.28%)	8,954 (14.48%)	1,626 (13.15%)	99,266 (20.85%)
65 - 74 years	35,291 (21.34%)	33,111 (20.81%)	16,428 (21.18%)	13,201 (21.35%)	2,402 (19.43%)	100,433 (21.09%)
75 - 84 years	30,163 (18.24%)	32,526 (20.45%)	21,208 (27.35%)	17,971 (29.07%)	3,487 (28.21%)	105,355 (22.12%)
85+ years	17,324 (10.48%)	21,006 (13.20%)	16,201 (20.89%)	13,185 (21.33%)	2,559 (20.70%)	70,275 (14.76%)
Sex						
Female	80,159 (48.47%)	81,404 (51.17%)	40,023 (51.61%)	31,375 (50.75%)	6,230 (50.39%)	239,191 (50.23%)
Male	83,570 (50.53%)	76,083 (47.83%)	36,813 (47.47%)	29,709 (48.05%)	5,984 (48.40%)	232,159 (48.75%)
Other	2 (0.00%)	2 (0.00%)	2 (0.00%)	0	0	6 (0.00%)
Unknown	1,651 (1.00%)	1,594 (1.00%)	714 (0.92%)	743 (1.20%)	149 (1.21%)	4,851 (1.02%)
Race						
White	105,784 (63.96%)	108,067 (67.93%)	53,842 (69.43%)	42,169 (68.20%)	8,412 (68.04%)	318,274 (66.84%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Black or African American	20,111 (12.16%)	18,502 (11.63%)	7,724 (9.96%)	6,626 (10.72%)	1,472 (11.91%)	54,435 (11.43%)
Asian	4,063 (2.46%)	3,524 (2.22%)	2,292 (2.96%)	1,856 (3.00%)	409 (3.31%)	12,144 (2.55%)
Native Hawaiian or Other Pacific Islander	843 (0.51%)	746 (0.47%)	300 (0.39%)	278 (0.45%)	39 (0.32%)	2,206 (0.46%)
American Indian or Alaska Native	956 (0.58%)	949 (0.60%)	411 (0.53%)	338 (0.55%)	81 (0.66%)	2,735 (0.57%)
Other Race	11,234 (6.79%)	8,256 (5.19%)	4,103 (5.29%)	3,081 (4.98%)	760 (6.15%)	27,434 (5.76%)
Unknown	22,391 (13.54%)	19,039 (11.97%)	8,880 (11.45%)	7,479 (12.10%)	1,190 (9.63%)	58,979 (12.39%)
Ethnicity						
Hispanic or Latino	18,909 (11.43%)	13,877 (8.72%)	6,340 (8.18%)	5,514 (8.92%)	1,076 (8.70%)	45,716 (9.60%)
Not Hispanic or Latino	121,805 (73.65%)	125,443 (78.85%)	61,979 (79.92%)	50,084 (81.01%)	10,386 (84.01%)	369,697 (77.63%)
Unknown	24,668 (14.92%)	19,763 (12.42%)	9,233 (11.91%)	6,229 (10.07%)	901 (7.29%)	60,794 (12.77%)
Comorbidity						
Asthma	13,076 (7.91%)	14,541 (9.14%)	7,788 (10.04%)	7,052 (11.41%)	1,554 (12.57%)	44,011 (9.24%)
Chronic Lung Disease	10,415 (6.30%)	10,356 (6.51%)	5,590 (7.21%)	5,030 (8.14%)	1,061 (8.58%)	32,452 (6.81%)
Chronic Obstructive Pulmonary Disease	18,040 (10.91%)	23,018 (14.47%)	13,408 (17.29%)	11,988 (19.39%)	2,487 (20.12%)	68,941 (14.48%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2020

Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 28,217,725 COVID lab results with known results of which 3,300,420 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2020

Figure 7: Weekly COVID test positivity rate by season

Influenza

Our influenza study population consists of 68,968 hospitalizations of 59,834 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	405 (100.00%)	4,937 (100.00%)	17,764 (100.00%)	20,507 (100.00%)	16,221 (100.00%)	59,834 (100.00%)
Age Group						
< 6 months	3 (0.74%)	28 (0.57%)	82 (0.46%)	89 (0.43%)	36 (0.22%)	238 (0.40%)
6 - <12 months	1 (0.25%)	18 (0.36%)	67 (0.38%)	52 (0.25%)	27 (0.17%)	165 (0.28%)
1 - <2 years	0	29 (0.59%)	122 (0.69%)	86 (0.42%)	55 (0.34%)	292 (0.49%)
2 - 4 years	3 (0.74%)	60 (1.22%)	267 (1.50%)	207 (1.01%)	84 (0.52%)	621 (1.04%)
5 - 17 years	6 (1.48%)	184 (3.73%)	598 (3.37%)	569 (2.77%)	272 (1.68%)	1,629 (2.72%)
18 - 49 years	112 (27.65%)	1,124 (22.77%)	3,531 (19.88%)	4,235 (20.65%)	2,687 (16.56%)	11,689 (19.54%)
50 - 64 years	103 (25.43%)	917 (18.57%)	3,701 (20.83%)	4,595 (22.41%)	3,563 (21.97%)	12,879 (21.52%)
65 - 74 years	71 (17.53%)	988 (20.01%)	3,818 (21.49%)	4,404 (21.48%)	3,686 (22.72%)	12,967 (21.67%)
75 - 84 years	76 (18.77%)	963 (19.51%)	3,543 (19.94%)	4,071 (19.85%)	3,607 (22.24%)	12,260 (20.49%)
85+ years	30 (7.41%)	626 (12.68%)	2,035 (11.46%)	2,199 (10.72%)	2,204 (13.59%)	7,094 (11.86%)
Sex						
Female	247 (60.99%)	2,790 (56.51%)	9,921 (55.85%)	11,173 (54.48%)	8,915 (54.96%)	33,046 (55.23%)
Male	153 (37.78%)	2,097 (42.48%)	7,706 (43.38%)	9,152 (44.63%)	7,162 (44.15%)	26,270 (43.90%)
Other	0	0	2 (0.01%)	0	0	2 (0.00%)
Unknown	5 (1.23%)	50 (1.01%)	135 (0.76%)	182 (0.89%)	144 (0.89%)	516 (0.86%)
Race						
White	260 (64.20%)	3,318 (67.21%)	11,779 (66.31%)	13,110 (63.93%)	10,443 (64.38%)	38,910 (65.03%)
Black or African American	74 (18.27%)	696 (14.10%)	2,447 (13.78%)	3,177 (15.49%)	2,568 (15.83%)	8,962 (14.98%)
Asian	6 (1.48%)	104 (2.11%)	467 (2.63%)	535 (2.61%)	459 (2.83%)	1,571 (2.63%)
Native Hawaiian or Other Pacific Islander	2 (0.49%)	42 (0.85%)	115 (0.65%)	152 (0.74%)	90 (0.55%)	401 (0.67%)
American Indian or Alaska Native	2 (0.49%)	45 (0.91%)	153 (0.86%)	131 (0.64%)	101 (0.62%)	432 (0.72%)
Other Race	13 (3.21%)	252 (5.10%)	1,112 (6.26%)	1,320 (6.44%)	1,062 (6.55%)	3,759 (6.28%)
Unknown	48 (11.85%)	480 (9.72%)	1,691 (9.52%)	2,082 (10.15%)	1,498 (9.23%)	5,799 (9.69%)
Ethnicity						
Hispanic or Latino	33 (8.15%)	500 (10.13%)	2,062 (11.61%)	2,522 (12.30%)	2,070 (12.76%)	7,187 (12.01%)
Not Hispanic or Latino	312 (77.04%)	3,961 (80.23%)	14,118 (79.48%)	16,388 (79.91%)	13,174 (81.22%)	47,953 (80.14%)
Unknown	60 (14.81%)	476 (9.64%)	1,584 (8.92%)	1,597 (7.79%)	977 (6.02%)	4,694 (7.85%)
Comorbidity						
Asthma	38 (9.38%)	761 (15.41%)	2,770 (15.59%)	3,181 (15.51%)	2,615 (16.12%)	9,365 (15.65%)
Chronic Lung Disease	30 (7.41%)	449 (9.09%)	1,614 (9.09%)	1,916 (9.34%)	1,594 (9.83%)	5,603 (9.36%)
Chronic Obstructive Pulmonary Disease	68 (16.79%)	1,067 (21.61%)	3,840 (21.62%)	4,267 (20.81%)	3,505 (21.61%)	12,747 (21.30%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 12,740,117 influenza lab results with known results of which 946,354 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2020

Figure 11: Weekly influenza test positivity rate by season

Human metapneumovirus (HMPV)

Our HMPV study population consists of 14,554 hospitalizations of 10,338 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	90 (100.00%)	2,323 (100.00%)	4,069 (100.00%)	3,258 (100.00%)	598 (100.00%)	10,338 (100.00%)
Age Group						
< 6 months	2 (2.22%)	58 (2.50%)	139 (3.42%)	70 (2.15%)	6 (1.00%)	275 (2.66%)
6 - <12 months	1 (1.11%)	69 (2.97%)	103 (2.53%)	80 (2.46%)	14 (2.34%)	267 (2.58%)
1 - <2 years	8 (8.89%)	124 (5.34%)	146 (3.59%)	80 (2.46%)	13 (2.17%)	371 (3.59%)
2 - 4 years	12 (13.33%)	184 (7.92%)	247 (6.07%)	130 (3.99%)	16 (2.68%)	589 (5.70%)
5 - 17 years	2 (2.22%)	99 (4.26%)	143 (3.51%)	93 (2.85%)	15 (2.51%)	352 (3.40%)
18 - 49 years	12 (13.33%)	274 (11.80%)	431 (10.59%)	406 (12.46%)	71 (11.87%)	1,194 (11.55%)
50 - 64 years	21 (23.33%)	425 (18.30%)	680 (16.71%)	572 (17.56%)	90 (15.05%)	1,788 (17.30%)
65 - 74 years	8 (8.89%)	421 (18.12%)	791 (19.44%)	661 (20.29%)	110 (18.39%)	1,991 (19.26%)
75 - 84 years	15 (16.67%)	427 (18.38%)	850 (20.89%)	720 (22.10%)	157 (26.25%)	2,169 (20.98%)
85+ years	9 (10.00%)	242 (10.42%)	539 (13.25%)	446 (13.69%)	106 (17.73%)	1,342 (12.98%)
Sex						
Female	42 (46.67%)	1,339 (57.64%)	2,364 (58.10%)	1,993 (61.17%)	355 (59.36%)	6,093 (58.94%)
Male	46 (51.11%)	966 (41.58%)	1,681 (41.31%)	1,241 (38.09%)	237 (39.63%)	4,171 (40.35%)
Unknown	2 (2.22%)	18 (0.77%)	24 (0.59%)	24 (0.74%)	6 (1.00%)	74 (0.72%)
Race						
White	60 (66.67%)	1,686 (72.58%)	2,891 (71.05%)	2,150 (65.99%)	425 (71.07%)	7,212 (69.76%)
Black or African American	8 (8.89%)	244 (10.50%)	362 (8.90%)	365 (11.20%)	56 (9.36%)	1,035 (10.01%)
Asian	1 (1.11%)	47 (2.02%)	116 (2.85%)	72 (2.21%)	14 (2.34%)	250 (2.42%)
Native Hawaiian or Other Pacific Islander	0	17 (0.73%)	14 (0.34%)	8 (0.25%)	1 (0.17%)	40 (0.39%)
American Indian or Alaska Native	0	12 (0.52%)	34 (0.84%)	18 (0.55%)	3 (0.50%)	67 (0.65%)
Other Race	10 (11.11%)	110 (4.74%)	289 (7.10%)	261 (8.01%)	50 (8.36%)	720 (6.96%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Unknown	11 (12.22%)	207 (8.91%)	363 (8.92%)	384 (11.79%)	49 (8.19%)	1,014 (9.81%)
Ethnicity						
Hispanic or Latino	19 (21.11%)	231 (9.94%)	566 (13.91%)	498 (15.29%)	98 (16.39%)	1,412 (13.66%)
Not Hispanic or Latino	57 (63.33%)	1,867 (80.37%)	3,193 (78.47%)	2,503 (76.83%)	466 (77.93%)	8,086 (78.22%)
Unknown	14 (15.56%)	225 (9.69%)	310 (7.62%)	257 (7.89%)	34 (5.69%)	840 (8.13%)
Comorbidity						
Asthma	11 (12.22%)	368 (15.84%)	648 (15.93%)	510 (15.65%)	106 (17.73%)	1,643 (15.89%)
Chronic Lung Disease	11 (12.22%)	282 (12.14%)	438 (10.76%)	314 (9.64%)	80 (13.38%)	1,125 (10.88%)
Chronic Obstructive Pulmonary Disease	17 (18.89%)	510 (21.95%)	837 (20.57%)	631 (19.37%)	143 (23.91%)	2,138 (20.68%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2020

Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 1,597,814 HMPV lab results with known results of which 39,730 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2020

Figure 15: Weekly HMPV test positivity rate by season

Parainfluenza virus

Our parainfluenza study population consists of 15,850 hospitalizations of 12,980 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	1,503 (100.00%)	2,435 (100.00%)	4,414 (100.00%)	3,658 (100.00%)	970 (100.00%)	12,980 (100.00%)
Age Group						
< 6 months	82 (5.46%)	126 (5.17%)	212 (4.80%)	121 (3.31%)	21 (2.16%)	562 (4.33%)
6 - <12 months	64 (4.26%)	90 (3.70%)	147 (3.33%)	79 (2.16%)	12 (1.24%)	392 (3.02%)
1 - <2 years	101 (6.72%)	119 (4.89%)	173 (3.92%)	134 (3.66%)	30 (3.09%)	557 (4.29%)
2 - 4 years	117 (7.78%)	202 (8.30%)	263 (5.96%)	153 (4.18%)	42 (4.33%)	777 (5.99%)
5 - 17 years	89 (5.92%)	129 (5.30%)	216 (4.89%)	123 (3.36%)	41 (4.23%)	598 (4.61%)
18 - 49 years	201 (13.37%)	303 (12.44%)	502 (11.37%)	402 (10.99%)	151 (15.57%)	1,559 (12.01%)
50 - 64 years	271 (18.03%)	420 (17.25%)	748 (16.95%)	661 (18.07%)	153 (15.77%)	2,253 (17.36%)
65 - 74 years	243 (16.17%)	427 (17.54%)	762 (17.26%)	713 (19.49%)	209 (21.55%)	2,354 (18.14%)
75 - 84 years	216 (14.37%)	358 (14.70%)	824 (18.67%)	788 (21.54%)	185 (19.07%)	2,371 (18.27%)
85+ years	119 (7.92%)	261 (10.72%)	567 (12.85%)	484 (13.23%)	126 (12.99%)	1,557 (12.00%)
Sex						
Female	775 (51.56%)	1,344 (55.20%)	2,376 (53.83%)	1,984 (54.24%)	521 (53.71%)	7,000 (53.93%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Male	714 (47.50%)	1,074 (44.11%)	1,997 (45.24%)	1,634 (44.67%)	439 (45.26%)	5,858 (45.13%)
Unknown	14 (0.93%)	17 (0.70%)	41 (0.93%)	40 (1.09%)	10 (1.03%)	122 (0.94%)
Race						
White	937 (62.34%)	1,530 (62.83%)	2,792 (63.25%)	2,282 (62.38%)	642 (66.19%)	8,183 (63.04%)
Black or African American	204 (13.57%)	295 (12.11%)	500 (11.33%)	447 (12.22%)	129 (13.30%)	1,575 (12.13%)
Asian	42 (2.79%)	98 (4.02%)	193 (4.37%)	108 (2.95%)	21 (2.16%)	462 (3.56%)
Native Hawaiian or Other Pacific Islander	5 (0.33%)	12 (0.49%)	19 (0.43%)	27 (0.74%)	1 (0.10%)	64 (0.49%)
American Indian or Alaska Native	15 (1.00%)	18 (0.74%)	37 (0.84%)	24 (0.66%)	2 (0.21%)	96 (0.74%)
Other Race	151 (10.05%)	230 (9.45%)	438 (9.92%)	328 (8.97%)	70 (7.22%)	1,217 (9.38%)
Unknown	149 (9.91%)	252 (10.35%)	435 (9.86%)	442 (12.08%)	105 (10.82%)	1,383 (10.65%)
Ethnicity						
Hispanic or Latino	167 (11.11%)	303 (12.44%)	576 (13.05%)	539 (14.73%)	140 (14.43%)	1,725 (13.29%)
Not Hispanic or Latino	1,168 (77.71%)	1,875 (77.00%)	3,411 (77.28%)	2,816 (76.98%)	769 (79.28%)	10,039 (77.34%)
Unknown	168 (11.18%)	257 (10.55%)	427 (9.67%)	303 (8.28%)	61 (6.29%)	1,216 (9.37%)
Comorbidity						
Asthma	236 (15.70%)	392 (16.10%)	709 (16.06%)	576 (15.75%)	160 (16.49%)	2,073 (15.97%)
Chronic Lung Disease	146 (9.71%)	269 (11.05%)	434 (9.83%)	413 (11.29%)	108 (11.13%)	1,370 (10.55%)
Chronic Obstructive Pulmonary Disease	323 (21.49%)	520 (21.36%)	934 (21.16%)	854 (23.35%)	254 (26.19%)	2,885 (22.23%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 1,680,707 parainfluenza lab results with known results of which 61,753 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2020

Figure 19: Weekly parainfluenza test positivity rate by season

Respiratory syncytial virus (RSV)

Our RSV study population consists of 38,152 hospitalizations of 29,997 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	2,054 (100.00%)	4,463 (100.00%)	8,106 (100.00%)	9,889 (100.00%)	5,485 (100.00%)	29,997 (100.00%)
Age Group						

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
< 6 months	506 (24.63%)	806 (18.06%)	1,412 (17.42%)	1,100 (11.12%)	376 (6.86%)	4,200 (14.00%)
6 - <12 months	134 (6.52%)	290 (6.50%)	509 (6.28%)	433 (4.38%)	238 (4.34%)	1,604 (5.35%)
1 - <2 years	185 (9.01%)	360 (8.07%)	565 (6.97%)	468 (4.73%)	286 (5.21%)	1,864 (6.21%)
2 - 4 years	164 (7.98%)	375 (8.40%)	726 (8.96%)	422 (4.27%)	294 (5.36%)	1,981 (6.60%)
5 - 17 years	47 (2.29%)	125 (2.80%)	259 (3.20%)	227 (2.30%)	115 (2.10%)	773 (2.58%)
18 - 49 years	191 (9.30%)	390 (8.74%)	615 (7.59%)	874 (8.84%)	583 (10.63%)	2,653 (8.84%)
50 - 64 years	265 (12.90%)	548 (12.28%)	935 (11.53%)	1,458 (14.74%)	864 (15.75%)	4,070 (13.57%)
65 - 74 years	246 (11.98%)	575 (12.88%)	1,110 (13.69%)	1,652 (16.71%)	948 (17.28%)	4,531 (15.10%)
75 - 84 years	196 (9.54%)	598 (13.40%)	1,163 (14.35%)	1,850 (18.71%)	1,055 (19.23%)	4,862 (16.21%)
85+ years	120 (5.84%)	396 (8.87%)	812 (10.02%)	1,405 (14.21%)	726 (13.24%)	3,459 (11.53%)
Sex						
Female	1,100 (53.55%)	2,289 (51.29%)	4,316 (53.24%)	5,422 (54.83%)	2,994 (54.59%)	16,121 (53.74%)
Male	945 (46.01%)	2,141 (47.97%)	3,717 (45.85%)	4,377 (44.26%)	2,448 (44.63%)	13,628 (45.43%)
Unknown	9 (0.44%)	33 (0.74%)	73 (0.90%)	90 (0.91%)	43 (0.78%)	248 (0.83%)
Race						
White	1,214 (59.10%)	2,872 (64.35%)	5,184 (63.95%)	6,444 (65.16%)	3,371 (61.46%)	19,085 (63.62%)
Black or African American	374 (18.21%)	524 (11.74%)	872 (10.76%)	1,111 (11.23%)	837 (15.26%)	3,718 (12.39%)
Asian	53 (2.58%)	198 (4.44%)	429 (5.29%)	355 (3.59%)	179 (3.26%)	1,214 (4.05%)
Native Hawaiian or Other Pacific Islander	17 (0.83%)	76 (1.70%)	144 (1.78%)	105 (1.06%)	94 (1.71%)	436 (1.45%)
American Indian or Alaska Native	15 (0.73%)	38 (0.85%)	64 (0.79%)	73 (0.74%)	33 (0.60%)	223 (0.74%)
Other Race	181 (8.81%)	334 (7.48%)	670 (8.27%)	646 (6.53%)	395 (7.20%)	2,226 (7.42%)
Unknown	200 (9.74%)	421 (9.43%)	743 (9.17%)	1,155 (11.68%)	576 (10.50%)	3,095 (10.32%)
Ethnicity						
Hispanic or Latino	281 (13.68%)	604 (13.53%)	1,206 (14.88%)	1,279 (12.93%)	814 (14.84%)	4,184 (13.95%)
Not Hispanic or Latino	1,560 (75.95%)	3,455 (77.41%)	6,169 (76.10%)	7,728 (78.15%)	4,318 (78.72%)	23,230 (77.44%)
Unknown	213 (10.37%)	404 (9.05%)	731 (9.02%)	882 (8.92%)	353 (6.44%)	2,583 (8.61%)
Comorbidity						
Asthma	238 (11.59%)	585 (13.11%)	1,066 (13.15%)	1,410 (14.26%)	868 (15.82%)	4,167 (13.89%)
Chronic Lung Disease	136 (6.62%)	310 (6.95%)	590 (7.28%)	823 (8.32%)	491 (8.95%)	2,350 (7.83%)
Chronic Obstructive Pulmonary Disease	284 (13.83%)	739 (16.56%)	1,387 (17.11%)	2,006 (20.29%)	1,097 (20.00%)	5,513 (18.38%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2020

Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 5,686,806 RSV lab results with known results of which 269,353 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2020

Figure 23: Weekly RSV test positivity rate by season

Weekly RSV test positivity rate by season

Rhinovirus

Our rhinovirus study population consists of 66,878 hospitalizations of 53,707 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	7,154 (100.00%)	9,886 (100.00%)	15,935 (100.00%)	14,655 (100.00%)	6,077 (100.00%)	53,707 (100.00%)
Age Group						
< 6 months	391 (5.47%)	703 (7.11%)	874 (5.48%)	710 (4.84%)	203 (3.34%)	2,881 (5.36%)
6 - <12 months	253 (3.54%)	388 (3.92%)	453 (2.84%)	380 (2.59%)	117 (1.93%)	1,591 (2.96%)
1 - <2 years	512 (7.16%)	798 (8.07%)	856 (5.37%)	690 (4.71%)	207 (3.41%)	3,063 (5.70%)
2 - 4 years	631 (8.82%)	1,267 (12.82%)	1,428 (8.96%)	1,010 (6.89%)	294 (4.84%)	4,630 (8.62%)
5 - 17 years	778 (10.88%)	1,218 (12.32%)	1,800 (11.30%)	1,475 (10.06%)	431 (7.09%)	5,702 (10.62%)
18 - 49 years	1,494 (20.88%)	1,442 (14.59%)	2,596 (16.29%)	2,606 (17.78%)	1,276 (21.00%)	9,414 (17.53%)
50 - 64 years	1,096 (15.32%)	1,262 (12.77%)	2,365 (14.84%)	2,245 (15.32%)	1,065 (17.53%)	8,033 (14.96%)
65 - 74 years	885 (12.37%)	1,236 (12.50%)	2,261 (14.19%)	2,239 (15.28%)	1,008 (16.59%)	7,629 (14.20%)
75 - 84 years	694 (9.70%)	958 (9.69%)	2,000 (12.55%)	1,965 (13.41%)	913 (15.02%)	6,530 (12.16%)
85+ years	420 (5.87%)	614 (6.21%)	1,302 (8.17%)	1,335 (9.11%)	563 (9.26%)	4,234 (7.88%)
Sex						
Female	3,560 (49.76%)	4,744 (47.99%)	7,900 (49.58%)	7,339 (50.08%)	3,018 (49.66%)	26,561 (49.46%)
Male	3,528 (49.32%)	5,057 (51.15%)	7,904 (49.60%)	7,162 (48.87%)	3,013 (49.58%)	26,664 (49.65%)
Unknown	66 (0.92%)	85 (0.86%)	131 (0.82%)	154 (1.05%)	46 (0.76%)	482 (0.90%)
Race						
White	4,209 (58.83%)	5,788 (58.55%)	9,246 (58.02%)	8,538 (58.26%)	3,802 (62.56%)	31,583 (58.81%)
Black or African American	1,120 (15.66%)	1,448 (14.65%)	2,273 (14.26%)	2,135 (14.57%)	948 (15.60%)	7,924 (14.75%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Asian	262 (3.66%)	440 (4.45%)	693 (4.35%)	414 (2.82%)	112 (1.84%)	1,921 (3.58%)
Native Hawaiian or Other Pacific Islander	47 (0.66%)	63 (0.64%)	69 (0.43%)	70 (0.48%)	20 (0.33%)	269 (0.50%)
American Indian or Alaska Native	41 (0.57%)	62 (0.63%)	121 (0.76%)	76 (0.52%)	40 (0.66%)	340 (0.63%)
Other Race	828 (11.57%)	1,166 (11.79%)	1,792 (11.25%)	1,637 (11.17%)	576 (9.48%)	5,999 (11.17%)
Unknown	647 (9.04%)	919 (9.30%)	1,741 (10.93%)	1,785 (12.18%)	579 (9.53%)	5,671 (10.56%)
Ethnicity						
Hispanic or Latino	896 (12.52%)	1,412 (14.28%)	2,489 (15.62%)	2,498 (17.05%)	1,022 (16.82%)	8,317 (15.49%)
Not Hispanic or Latino	5,549 (77.56%)	7,569 (76.56%)	11,881 (74.56%)	10,875 (74.21%)	4,712 (77.54%)	40,586 (75.57%)
Unknown	709 (9.91%)	905 (9.15%)	1,565 (9.82%)	1,282 (8.75%)	343 (5.64%)	4,804 (8.94%)
Comorbidity						
Asthma	1,339 (18.72%)	1,687 (17.06%)	2,714 (17.03%)	2,505 (17.09%)	1,101 (18.12%)	9,346 (17.40%)
Chronic Lung Disease	664 (9.28%)	748 (7.57%)	1,243 (7.80%)	1,111 (7.58%)	599 (9.86%)	4,365 (8.13%)
Chronic Obstructive Pulmonary Disease	1,204 (16.83%)	1,442 (14.59%)	2,440 (15.31%)	2,308 (15.75%)	1,180 (19.42%)	8,574 (15.96%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season

Test positivity rate over time

We included 1,565,970 rhinovirus lab results with known results of which 251,101 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2020

Figure 27: Weekly rhinovirus test positivity rate by season

Infants and children (age 0-4)

Our infants and children study population consists of 42,392 hospitalizations of 32,282 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	3,781 (100.00%)	7,842 (100.00%)	9,889 (100.00%)	7,674 (100.00%)	3,096 (100.00%)	32,282 (100.00%)
Age Group						
< 6 months	1,301 (34.41%)	2,494 (31.80%)	3,149 (31.84%)	2,463 (32.10%)	796 (25.71%)	10,203 (31.61%)
6 - <12 months	510 (13.49%)	1,126 (14.36%)	1,493 (15.10%)	1,253 (16.33%)	507 (16.38%)	4,889 (15.14%)
1 - <2 years	911 (24.09%)	1,708 (21.78%)	2,055 (20.78%)	1,724 (22.47%)	788 (25.45%)	7,186 (22.26%)
2 - 4 years	1,059 (28.01%)	2,514 (32.06%)	3,192 (32.28%)	2,234 (29.11%)	1,005 (32.46%)	10,004 (30.99%)
Sex						
Female	1,588 (42.00%)	3,262 (41.60%)	4,284 (43.32%)	3,330 (43.39%)	1,318 (42.57%)	13,782 (42.69%)
Male	2,192 (57.97%)	4,566 (58.22%)	5,595 (56.58%)	4,332 (56.45%)	1,776 (57.36%)	18,461 (57.19%)
Unknown	1 (0.03%)	14 (0.18%)	10 (0.10%)	12 (0.16%)	2 (0.06%)	39 (0.12%)
Race						
White	1,770 (46.81%)	3,801 (48.47%)	4,642 (46.94%)	3,455 (45.02%)	1,394 (45.03%)	15,062 (46.66%)
Black or African American	743 (19.65%)	1,304 (16.63%)	1,522 (15.39%)	1,198 (15.61%)	524 (16.93%)	5,291 (16.39%)
Asian	188 (4.97%)	510 (6.50%)	794 (8.03%)	485 (6.32%)	182 (5.88%)	2,159 (6.69%)
Native Hawaiian or Other Pacific Islander	72 (1.90%)	171 (2.18%)	204 (2.06%)	192 (2.50%)	98 (3.17%)	737 (2.28%)
American Indian or Alaska Native	30 (0.79%)	71 (0.91%)	118 (1.19%)	57 (0.74%)	21 (0.68%)	297 (0.92%)
Other Race	687 (18.17%)	1,253 (15.98%)	1,594 (16.12%)	1,217 (15.86%)	511 (16.51%)	5,262 (16.30%)
Unknown	291 (7.70%)	732 (9.33%)	1,015 (10.26%)	1,070 (13.94%)	366 (11.82%)	3,474 (10.76%)
Ethnicity						
Hispanic or Latino	767 (20.29%)	1,666 (21.24%)	2,458 (24.86%)	1,939 (25.27%)	804 (25.97%)	7,634 (23.65%)
Not Hispanic or Latino	2,724 (72.04%)	5,613 (71.58%)	6,681 (67.56%)	5,141 (66.99%)	2,081 (67.22%)	22,240 (68.89%)
Unknown	290 (7.67%)	563 (7.18%)	750 (7.58%)	594 (7.74%)	211 (6.82%)	2,408 (7.46%)
Virus						
COVID	611 (16.16%)	1,748 (22.29%)	1,098 (11.10%)	1,180 (15.38%)	725 (23.42%)	5,362 (16.61%)
HMPV	23 (0.61%)	435 (5.55%)	635 (6.42%)	360 (4.69%)	49 (1.58%)	1,502 (4.65%)
RSV	989 (26.16%)	1,831 (23.35%)	3,212 (32.48%)	2,423 (31.57%)	1,194 (38.57%)	9,649 (29.89%)
influenza	7 (0.19%)	135 (1.72%)	538 (5.44%)	434 (5.66%)	202 (6.52%)	1,316 (4.08%)
parainfluenza	364 (9.63%)	537 (6.85%)	795 (8.04%)	487 (6.35%)	105 (3.39%)	2,288 (7.09%)
rhinovirus	1,787 (47.26%)	3,156 (40.24%)	3,611 (36.52%)	2,790 (36.36%)	821 (26.52%)	12,165 (37.68%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Comorbidity						
Asthma	282 (7.46%)	496 (6.32%)	658 (6.65%)	518 (6.75%)	268 (8.66%)	2,222 (6.88%)
Chronic Lung Disease	22 (0.58%)	42 (0.54%)	64 (0.65%)	60 (0.78%)	18 (0.58%)	206 (0.64%)
Chronic Obstructive Pulmonary Disease	4 (0.11%)	12 (0.15%)	13 (0.13%)	16 (0.21%)	1 (0.03%)	46 (0.14%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five

Test positivity rate over time

We included 5,195,392 lab results with known results of infants and children under age five. Of those tests, 589,056 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2020 for infants and children under five

Older adults (age 65 and over)

Our older adults study population consists of 377,839 hospitalizations of 351,413 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	86,126 (100.00%)	95,733 (100.00%)	76,214 (100.00%)	69,289 (100.00%)	24,051 (100.00%)	351,413 (100.00%)
Age Group						
65 - 74 years	36,744 (42.66%)	36,758 (38.40%)	25,170 (33.03%)	22,870 (33.01%)	8,363 (34.77%)	129,905 (36.97%)
75 - 84 years	31,360 (36.41%)	35,830 (37.43%)	29,588 (38.82%)	27,365 (39.49%)	9,404 (39.10%)	133,547 (38.00%)
85+ years	18,022 (20.93%)	23,145 (24.18%)	21,456 (28.15%)	19,054 (27.50%)	6,284 (26.13%)	87,961 (25.03%)
Sex						
Female	42,079 (48.86%)	48,088 (50.23%)	40,121 (52.64%)	36,322 (52.42%)	12,952 (53.85%)	179,562 (51.10%)
Male	43,744 (50.79%)	47,254 (49.36%)	35,712 (46.86%)	32,507 (46.92%)	10,860 (45.15%)	170,077 (48.40%)
Unknown	303 (0.35%)	391 (0.41%)	381 (0.50%)	460 (0.66%)	239 (0.99%)	1,774 (0.50%)
Race						
White	62,183 (72.20%)	71,963 (75.17%)	57,164 (75.00%)	50,548 (72.95%)	17,698 (73.59%)	259,556 (73.86%)
Black or African American	7,068 (8.21%)	7,419 (7.75%)	5,524 (7.25%)	5,727 (8.27%)	2,355 (9.79%)	28,093 (7.99%)
Asian	1,590 (1.85%)	1,770 (1.85%)	1,960 (2.57%)	1,768 (2.55%)	643 (2.67%)	7,731 (2.20%)
Native Hawaiian or Other Pacific Islander	150 (0.17%)	189 (0.20%)	166 (0.22%)	158 (0.23%)	52 (0.22%)	715 (0.20%)
American Indian or Alaska Native	248 (0.29%)	322 (0.34%)	318 (0.42%)	280 (0.40%)	105 (0.44%)	1,273 (0.36%)
Other Race	3,122 (3.62%)	2,839 (2.97%)	2,933 (3.85%)	2,832 (4.09%)	1,013 (4.21%)	12,739 (3.63%)
Unknown	11,765 (13.66%)	11,231 (11.73%)	8,149 (10.69%)	7,976 (11.51%)	2,185 (9.08%)	41,306 (11.75%)
Ethnicity						
Hispanic or Latino	4,582 (5.32%)	4,121 (4.30%)	4,254 (5.58%)	4,760 (6.87%)	1,845 (7.67%)	19,562 (5.57%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Not Hispanic or Latino	66,970 (77.76%)	78,295 (81.78%)	62,628 (82.17%)	57,393 (82.83%)	20,569 (85.52%)	285,855 (81.34%)
Unknown	14,574 (16.92%)	13,317 (13.91%)	9,332 (12.24%)	7,136 (10.30%)	1,637 (6.81%)	45,996 (13.09%)
Virus						
COVID	82,778 (96.11%)	86,643 (90.50%)	53,837 (70.64%)	44,357 (64.02%)	8,448 (35.13%)	276,063 (78.56%)
HMPV	32 (0.04%)	1,090 (1.14%)	2,180 (2.86%)	1,827 (2.64%)	373 (1.55%)	5,502 (1.57%)
RSV	562 (0.65%)	1,569 (1.64%)	3,085 (4.05%)	4,907 (7.08%)	2,729 (11.35%)	12,852 (3.66%)
influenza	177 (0.21%)	2,577 (2.69%)	9,396 (12.33%)	10,674 (15.41%)	9,497 (39.49%)	32,321 (9.20%)
parainfluenza	578 (0.67%)	1,046 (1.09%)	2,153 (2.82%)	1,985 (2.86%)	520 (2.16%)	6,282 (1.79%)
rhinovirus	1,999 (2.32%)	2,808 (2.93%)	5,563 (7.30%)	5,539 (7.99%)	2,484 (10.33%)	18,393 (5.23%)
Comorbidity						
Asthma	6,538 (7.59%)	8,355 (8.73%)	7,957 (10.44%)	7,830 (11.30%)	3,157 (13.13%)	33,837 (9.63%)
Chronic Lung Disease	6,413 (7.45%)	7,495 (7.83%)	6,753 (8.86%)	6,517 (9.41%)	2,640 (10.98%)	29,818 (8.49%)
Chronic Obstructive Pulmonary Disease	14,722 (17.09%)	20,031 (20.92%)	17,495 (22.96%)	17,004 (24.54%)	6,501 (27.03%)	75,753 (21.56%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older

Test positivity rate over time

We included 15,275,809 lab results with known results of adults aged 65 and over. Of those tests, 1,107,218 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2020 for adults 65 years or older

Discussion and conclusion

In the week of January 27, 2025, respiratory virus-associated hospitalizations accounted for 9.6% of all hospitalizations, a slight increase from 9.3% in late December (+3.1%). The largest increase in hospitalization rates was observed for influenza (+53.8%), rising from 4.4% to 6.8% of all hospitalizations. In contrast, notable declines were seen for all other respiratory viruses; COVID (-28.2%), RSV (-50.5%), rhinovirus (- 35.0%), HMPV (-26.2%), and parainfluenza (-47.7%). Influenza test positivity saw the largest increase (+52.6%) between the last full week of December 2024 and January 2025, rising by 8.5 percentage points to 24.6%. Test positivity for all other respiratory viruses declined. This marks the highest recorded rate of influenza-associated hospitalizations in these data. The rate of influenza-associated hospitalizations associated is 1.8-fold greater than last season.

In the population aged 0–4 years, respiratory virus-associated hospitalizations declined by 27.6% from late December to the week of January 27, now accounting for 5.3% of all hospitalizations in this age group. However, trends varied across specific viruses. Influenza-associated hospitalizations saw the largest increase (+91.2%), rising by 0.7 percentage points to 1.4%. The current rate of influenza-associated hospitalizations is 2-fold higher than the peak of last season for this age group. Conversely, RSV-associated hospitalizations experienced the sharpest decline (-69.8%), dropping by 3.6 percentage points to 1.5%. Notable decreases were also recorded for COVID (-33.2%), HMPV (-18.5%), and parainfluenza (-53.4%). Rhinovirus hospitalizations, however, increased by 53.7% (+0.7 percentage points). Influenza test positivity also saw the largest increase (+54.6%), rising by 9.7 percentage points to 27.6% between the end of December 2024 and the end of January 2025. Rhinovirus test positivity also rose (+15.9%). In contrast, RSV test positivity dropped sharply (-49.7%), while declines were also observed for COVID (-13.8%), HMPV (-6.6%), and parainfluenza (-55.3%). These shifts indicate a changing respiratory virus landscape in young children, with influenza- and rhinovirus-associated hospitalizations increasing, while RSV- and other respiratory viruses-associated hospitalizations decline.

Among older adults (age 65 and over), there was a minimal increase in respiratory virus-associated hospitalizations from late December to the end of January 2025 (+0.4%). Respiratory virus-associated hospitalizations now account for 11.9% of hospitalizations in this age group. However, large shifts were observed among specific viruses. Influenza-associated hospitalizations saw the largest increase (+57.1%), rising by 3.1 percentage points to 8.4% of all hospitalizations in this age group. The current rate of influenza-associated hospitalizations is 2-fold higher than the peak of last season for this age group. Conversely, notable declines were recorded for RSV- (- 46.1%), COVID- (-34.1%), rhinovirus- (-51.8%), HMPV- (-28.9%), and parainfluenza-associated (- 54.5%) hospitalizations. RSV- and COVID-associated hospitalizations now account for 1.1% and 2.4% of all hospitalizations in this population. Influenza test positivity saw the largest increase (+57.9%), rising by 6.7 percentage points to 18.3% between December 2024 and January 2025. Test positivity for all other respiratory viruses decreased during this period. These trends highlight the evolving landscape of respiratory virus impact in older adults, with influenza emerging as an increasing concern as other respiratory viruses decline.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed February 13, 2025. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when

laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., … Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth

Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., … Nair, H. (2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy